CRDF vs. ESPR, ORGO, CMPX, BCYC, PRTA, RGNX, SLDB, CTMX, FULC, and INBX
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Esperion Therapeutics (ESPR), Organogenesis (ORGO), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Prothena (PRTA), REGENXBIO (RGNX), Solid Biosciences (SLDB), CytomX Therapeutics (CTMX), Fulcrum Therapeutics (FULC), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Cardiff Oncology (NASDAQ:CRDF) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Esperion Therapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Esperion Therapeutics and 3 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.67 beat Esperion Therapeutics' score of 0.44 indicating that Cardiff Oncology is being referred to more favorably in the media.
Cardiff Oncology presently has a consensus price target of $10.63, suggesting a potential upside of 377.53%. Esperion Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 107.41%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Esperion Therapeutics.
Esperion Therapeutics has a net margin of -35.84% compared to Cardiff Oncology's net margin of -9,344.14%. Esperion Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.
Cardiff Oncology has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Cardiff Oncology has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiff Oncology and Esperion Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 10/6/2025 by MarketBeat.com Staff
